Company: BSX
Filing Date: 2025-08-01
Form Type: 10-Q
Source: 0000885725-25-000041
Chunk: 74

Company: BOSTON SCIENTIFIC CORP
Filing Date: 2025-08-01
Form: 10-Q
Item: Part I, Item 1
Chunk 74
---
028 (1) Includes royalty expense.(2) Calculated as Net sales of reportable segments less Segment expenses. Three Months EndedJune 30,Six Months EndedJune 30,Depreciation expense (in millions)2025202420252024MedSurg$28 $27 $55 $52 Cardiovascular83 71 162 136 Consolidated depreciation expense$111 $98 $217 $188 As ofTotal assets (in millions)June 30, 2025December 31, 2024MedSurg$3,331 $3,093 Cardiovascular7,498 7,084 Total assets of reportable segments10,829 10,177 Goodwill18,076 17,089 Other intangible assets, net7,260 6,684 All other corporate assets5,395 5,446  $41,559 $39,395 

33

As ofLong-lived assets (in millions)June 30, 2025December 31, 2024U.S.$1,530 $1,461 Ireland701 631 Costa Rica574 530 Other countries656 672 Property, plant and equipment, net3,461 3,294 Goodwill18,076 17,089 Other intangible assets, net7,260 6,684 Operating lease right-of-use assets in Other long-term assets492 449  $29,288 $27,516 

34

NOTE K – REVENUE We generate revenue primarily from the sale of single-use medical devices and present revenue net of sales taxes within our accompanying unaudited consolidated statements of operations. Our business structure is organized into five operating segments. The following tables disaggregate our revenue from contracts with customers by business unit and geographic region (in millions). Generally, we allocate revenue from contracts with customers to geographic regions based on the location where the sale originated.Three Months Ended June 30,20252024BusinessesU.S.Int'lTotalU.S.Int'lTotalEndoscopy$456 $281 $737 $415 $261 $676 Urology499 178 676 363 162 525 Neuromodulation228 75 303 214 68 282 MedSurg1,183 534 1,716 992 491 1,483 Int